Reilly Joseph James sold $15K of ARDX

Reilly Joseph James (See Remarks) sold 3,982 shares of ARDELYX, INC. (ARDX) at $3.86 across 2 trades on 2026-08-21.

Original reporting
SEC EDGAR · Reilly Joseph James
Published Aug 25, 2026, 11:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 11:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARDX
Neutral
high confidence
Mentioned
$ARDX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARDXNeutralLow
01

Why it matters

The sale represents a small reduction in insider ownership, unlikely to alter investor perception.

02

Market read

Limited relevance; primarily of interest to shareholders monitoring insider activity.

03

What to watch

Potential tax‑loss harvesting or portfolio rebalancing motives unrelated to company fundamentals.

Relevance 3/10Novelty 4/10Timing: filed 2026-08-25, immediate but low impact

Background

Form 4 filings provide transparent disclosure of insider trades; this sale is part of routine equity management.

Company-level read

Ticker impact

$ARDXNeutralHigh confidence
Context

Officer Reilly Joseph James sold 3,982 shares of ARDX for $15,358, a routine insider sale disclosed via Form 4.

Expected impact

Minor downward bias, likely within normal volatility range.

Evidence & confidence

The transaction size is modest relative to total holdings and market cap; no change in control or strategic direction.

Market effects

None; ARDX operates in a niche biotech segment with limited sector ripple.

No regional effect; transaction is company‑specific.

Minimal; insider sale of a micro‑cap does not affect broader markets.

Counterpoint

If the insider is privy to upcoming negative news, the sell could foreshadow a future decline.

Key entities

  • Reilly Joseph James

    Officer of ARDELYX, Inc. who executed the sale.

  • ARDELYX, Inc.

    Biotech firm listed under ticker ARDX.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ARDXMed

Ardelyx (ARDX) Q3 2026 Earnings Call Transcript

Ardelyx (ARDX) reported Q3 2026 revenue of $125.5M, up 19% YoY. IBSRELA revenue grew 23% to $96.3M, while XPHOZAH revenue rose 7% to $29.2M. The company reaffirmed its full-year guidance and expects profitability in 2027. Ardelyx has $285.3M in cash and is advancing its ACCEL Phase III trial for chronic idiopathic constipation.

$ARDXLow

Ardelyx Inc (ARDX) (Q3 2026) Earnings Call Highlights: Revenue Climbs 19% as IBSRELA Shines

Ardelyx Inc (ARDX) reported a 19% revenue increase in Q3 2026, driven by its IBSRELA drug. CEO Michael Raab and CFO Sue Hohenleitner addressed prescription trends, payer negotiations, and the company's IBSRELA Pharmacy Network (IPN). They reaffirmed guidance, citing strong fundamentals and positive early indicators from a DTC campaign. The company also discussed its Phase 3 ACCEL trial for CIC and inventory dynamics for XPHOZAH.

$ARDXMedAI 8/10

What Ardelyx (ARDX) Said on Its Q3 Earnings Call

Ardelyx (ARDX) reported Q3 revenue of $29.2M for XPHOZAH, up 7% YoY. Paid prescriptions rose 22%, but demand was offset by customer buying patterns. The company maintained its full-year revenue outlook of $110M-$120M. Ardelyx also launched a direct-to-consumer ad campaign for IBSRELA, with 91% of patients expressing interest. R&D expenses increased to $25.2M, and the company reported a net loss of $700K. Ardelyx expects to reach profitability in 2027, with a gross profit margin exceeding 95%.